Safety and Immunogenicity of the 2015-2016 Formulation of Fluzone® Quadrivalent (Influenza Vaccine) Among Healthy Children

PHASE4CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

August 31, 2015

Primary Completion Date

December 31, 2015

Study Completion Date

July 31, 2016

Conditions
Influenza
Interventions
BIOLOGICAL

Fluzone® Quadrivalent Influenza Vaccine, No Preservative

0.25 mL, Intramuscular (Pediatric Dose, 2015 2016 formulation)

BIOLOGICAL

Fluzone® Quadrivalent Influenza Vaccine, No Preservative

0.5 mL, Intramuscular (2015 2016 formulation)

Trial Locations (2)

40040

Bardstown

84121

Salt Lake City

All Listed Sponsors
lead

Sanofi Pasteur, a Sanofi Company

INDUSTRY

NCT02539108 - Safety and Immunogenicity of the 2015-2016 Formulation of Fluzone® Quadrivalent (Influenza Vaccine) Among Healthy Children | Biotech Hunter | Biotech Hunter